These findings underscore the consistent and widespread association of elevated ZDHHC3 expression across diverse cancer types and suggest a potential crosstalk between ZDHHC3 and PD-L1-dependent immune regulatory pathways, which also highlights the potential therapeutic targeting role of ZDHHC3 in treating different cancers. This evidence concerns the gene CD274 and cancer.